Cognitive Nootropic Peptides: Semax, Selank, Dihexa & Noopept Research Comparison

Peptide research has expanded well beyond musculoskeletal and metabolic targets to encompass central nervous system (CNS) applications — including anxiety modulation, cognitive enhancement, neuroprotection, sleep regulation, and neuroinflammation. Exceed Enhancement stocks four peptides with significant neuroscience research profiles: Selank, Semax, Epithalon, and DSIP (Delta Sleep-Inducing Peptide). While each influences the brain, they do so through distinct mechanisms and have distinct primary research applications. This guide compares them systematically for researchers navigating the peptide neuroscience landscape. All content is for scientific and educational reference only; these compounds are not approved for human therapeutic use.

Overview: Four Approaches to CNS Peptide Research

These four peptides represent different CNS research paradigms:

• Selank — anxiolytic and immunomodulatory peptide; enkephalin analog; GABA-A modulation
• Semax — ACTH/MSH analog; BDNF upregulation; cognitive and neuroprotective focus
• Epithalon (Epitalon) — pineal gland peptide; telomerase activation; circadian and anti-aging research
• DSIP — endogenous neuropeptide; sleep architecture modulation; HPA axis regulation

Selank

Structure and Origin

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was designed as a stable analog of the endogenous neuropeptide tuftsin (Thr-Lys-Pro-Arg), extended with the sequence Pro-Gly-Pro to enhance metabolic stability and CNS penetration. Tuftsin itself is a natural immunomodulatory tetrapeptide cleaved from immunoglobulin G, with recognized effects on immune cell activation and anxiety-related behavior.

Primary Mechanisms

GABAergic modulation: Selank’s most prominent CNS effect is anxiolytic activity mediated through GABA-A receptor modulation — similar in profile to benzodiazepines but without receptor agonism at the benzodiazepine binding site. Research has shown Selank modulates GABA-A receptor expression and function, increasing inhibitory tone without producing the sedation, tolerance, or dependence associated with classical benzodiazepines. This makes it a subject of considerable interest in anxiety disorder models requiring anxiolysis without GABAergic side effects.

Enkephalin metabolism: Selank inhibits enkephalinase enzymes — prolonging the half-life and activity of endogenous met-enkephalin and leu-enkephalin. Enkephalins are endogenous opioid peptides with stress-buffering, anti-anxiety, and mood-stabilizing roles in limbic system circuits.

BDNF and neurotrophin upregulation: Research in rodent models has demonstrated Selank increases brain-derived neurotrophic factor (BDNF) expression in hippocampus and prefrontal cortex — relevant to cognitive resilience, synaptic plasticity, and depression/anxiety neurobiology.

Immunomodulation: Consistent with its tuftsin lineage, Selank modulates IL-6, IL-1β, TNF-α, and interferon expression, positioning it also in neuroimmunology research studying the bidirectional CNS-immune axis in stress and anxiety disorders.

Research Applications

• Anxiety disorder models (generalized anxiety, stress-induced anxiety)
• Benzodiazepine-alternative anxiolytic research
• Cognitive performance under stress
• Neuroimmune interaction studies
• BDNF-mediated neuroprotection and synaptic plasticity

Semax

Structure and Origin

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the 4–10 fragment of adrenocorticotropic hormone (ACTH 4–10) — the melanocortin receptor-binding region responsible for ACTH’s cognitive and neuroprotective effects, absent its adrenal (cortisol-stimulating) activity. Like Selank, the Pro-Gly-Pro tripeptide was appended to the C-terminus to increase metabolic stability and CNS activity duration. Semax was developed by the same Russian research groups as Selank and has been studied extensively for neuroprotective, cognitive-enhancing, and stroke-related applications.

Primary Mechanisms

BDNF upregulation — the primary mechanism: Semax is the most potent BDNF-upregulating peptide in this group. Studies in rodents demonstrate robust increases in BDNF and its receptor TrkB in the hippocampus, cortex, and cerebellum following Semax administration. BDNF is the master regulator of neuroplasticity — essential for long-term potentiation (LTP), memory consolidation, neuronal survival, and recovery from ischemic or traumatic brain injury. Semax’s pronounced BDNF induction underpins most of its observed cognitive and neuroprotective effects.

Melanocortin receptor (MCR) activity: Semax retains melanocortin receptor-binding capacity from its ACTH 4–10 core. MC4R and MC2R activation in the CNS is associated with attention, motivation, learning, and memory — consistent with the cognitive-enhancing profile observed in Semax research.

Dopaminergic and serotonergic modulation: Semax has demonstrated effects on dopamine turnover in prefrontal and limbic regions, and serotonergic modulation relevant to mood, attention, and executive function research.

Neuroprotection and cerebral ischemia: Among peptide research compounds, Semax has one of the strongest preclinical neuroprotection profiles. In rat stroke models, Semax administration reduces infarct volume, preserves neurological function, and accelerates behavioral recovery — effects attributed to BDNF upregulation, anti-inflammatory actions, and promotion of neurovascular repair mechanisms.

Research Applications

• Cognitive enhancement and learning/memory research
• BDNF-mediated neuroplasticity and synaptic function
• Stroke, TBI, and cerebral ischemia recovery models
• Attention and executive function research (ADHD models)
• Neurodegeneration and neuroprotection (Alzheimer’s, Parkinson’s preclinical models)
• Mood and dopaminergic regulation research

Epithalon (Epitalon)

Structure and Origin

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is based on epithalamin — a natural peptide fraction isolated from the bovine pineal gland — and is the most studied of the “short peptide bioregulator” class developed by Khavinson’s group over several decades of research on peptide-based gerontological interventions.

Primary Mechanisms

Telomerase activation — the most discussed mechanism: Epithalon’s most-cited property is activation of telomerase (hTERT — human telomerase reverse transcriptase), the enzyme responsible for maintaining telomere length during cell division. Telomere attrition is a primary driver of cellular senescence; telomerase reactivation in somatic cells represents a theoretical lever for extending cellular replicative lifespan. In vitro studies have demonstrated that Epithalon increases telomerase activity in human cells and extends the replicative capacity of cultured fetal fibroblasts beyond the normal Hayflick limit. These findings position Epithalon prominently in cellular aging and longevity research, though the in vivo translation and safety implications of chronic telomerase activation in non-germline cells remain active research questions.

Pineal gland and melatonin regulation: Epithalon was derived from the pineal gland and has demonstrated effects on pineal melatonin synthesis — stimulating melatonin production in older subjects where age-related pineal calcification and melatonin decline are observed. This positions Epithalon in circadian rhythm research, age-related sleep disruption models, and neuroendocrine aging studies.

Antioxidant activity: Multiple in vitro and in vivo studies have demonstrated Epithalon reduces oxidative stress markers — lipid peroxidation, reactive oxygen species (ROS), and increases superoxide dismutase (SOD) and catalase activity. This antioxidant capacity is relevant to its anti-aging and neuroprotective research applications.

Epigenetic modulation: Khavinson’s research group has proposed that short peptide bioregulators including Epithalon modulate gene expression through histone interaction and chromatin remodeling — influencing expression of genes related to cell survival, differentiation, and aging. This epigenetic hypothesis remains an active and debated area of peptide biology.

Research Applications

• Telomere biology and cellular aging research
• Telomerase activation and replicative senescence models
• Pineal-melatonin axis and circadian rhythm regulation
• Age-related neuroendocrine decline models
• Antioxidant and oxidative stress research
• Longevity and lifespan extension research in model organisms

DSIP (Delta Sleep-Inducing Peptide)

Structure and Origin

DSIP is an endogenous neuropeptide nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit cerebral venous blood by Monnier and colleagues in 1977 following electrical stimulation of the thalamus. Its name reflects its original identification as a factor inducing slow-wave (delta) sleep when infused into recipient rabbits — though subsequent research has revealed a much broader and complex pharmacological profile than simple sleep induction.

Primary Mechanisms

Sleep architecture modulation: DSIP’s original characterization was based on its ability to increase slow-wave sleep (SWS/delta sleep, NREM stages 3–4) and REM sleep while reducing sleep latency in animal models. Subsequent human studies showed more variable results — with some demonstrating normalization of disrupted sleep architecture rather than sedation per se. DSIP appears to act more as a sleep-regulatory modulator than a direct hypnotic, making it relevant to research on sleep architecture quality rather than simply sleep quantity.

HPA axis regulation: DSIP has significant hypothalamic-pituitary-adrenal (HPA) axis activity — it modulates ACTH and cortisol secretion, inhibits corticotropin releasing factor (CRF), and has demonstrated stress-buffering effects in animal models. This dual sleep-HPA axis profile makes DSIP particularly relevant to research on stress-induced sleep disruption and circadian cortisol dysregulation.

GH and LH modulation: DSIP has been reported to influence GH and LH pulsatility in some research models — consistent with its hypothalamic activity and possible role as a broader neuroendocrine modulator rather than a purely somnogenic peptide.

Antioxidant properties: Like Epithalon, DSIP has demonstrated antioxidant activity in preclinical studies — reducing oxidative damage in aging and stress models, with some long-term rodent studies reporting lifespan extension and reduced tumor incidence.

Opioid system interaction: DSIP interacts with mu-opioid and sigma receptors, which may contribute to its analgesic and stress-modulatory properties reported in some research contexts.

Research Applications

• Sleep architecture and slow-wave sleep research
• Insomnia and circadian disruption models
• HPA axis and stress-response modulation
• Cortisol and ACTH regulation in chronic stress models
• Opioid withdrawal and substance dependence research
• Antioxidant and anti-aging studies

Head-to-Head Comparison

Selank vs. Semax: The Anxiety-Cognition Axis

Selank and Semax are the most frequently compared CNS peptides, often grouped as the “Russian cognitive peptides.” Despite superficial similarities (both synthetic heptapeptides stabilized with Pro-Gly-Pro, both with CNS-active profiles), they have meaningfully different primary targets:

• Selank is primarily anxiolytic — its cognitive effects are largely secondary to anxiety reduction and enkephalin enhancement; it is the preferred compound for models where anxiety is the primary target and cognitive improvement is desired without stimulatory side effects
• Semax is primarily pro-cognitive and neuroprotective — its anxiolytic effects are secondary; it is preferred for research focused on BDNF upregulation, learning and memory, and neurological recovery from ischemic events

In research protocols requiring both anxiolytic and cognitive-enhancing effects, both peptides have been studied together — with some researchers hypothesizing complementary and potentially synergistic profiles.

Epithalon vs. DSIP: Sleep and Aging Research

Epithalon and DSIP both have sleep-relevant research profiles, but from different angles:

• DSIP directly modulates sleep architecture — particularly slow-wave and REM sleep — and is the primary choice for studies targeting sleep quality, circadian rhythm, and HPA-axis-related sleep disruption
• Epithalon influences sleep indirectly via pineal-melatonin axis restoration — its sleep-relevant effects are most pronounced in aged research subjects where melatonin production has declined; it is the primary choice for studies situating sleep disruption within the broader context of neuroendocrine aging

Route of Administration and Stability

All four peptides are available as lyophilized powders requiring reconstitution. Route of administration varies in research literature:

• Selank: Originally researched via intranasal route in many human studies (achieves direct CNS delivery via olfactory epithelium); subcutaneous injection is also used in animal models
• Semax: Same as Selank — intranasal administration has been the primary clinical research route; injectable preparations also studied
• Epithalon: Most commonly studied via subcutaneous or intraperitoneal injection in animal research; intravenous routes used in some human studies
• DSIP: Primarily intravenous in early human studies; subcutaneous in more recent animal research; poor oral bioavailability for all four peptides

Storage and Reconstitution

All four compounds are lyophilized peptide powders. Standard research storage recommendations:

• Lyophilized (unreconstituted): store at −20°C for long-term; 2–8°C acceptable for short-term use
• Reconstitute with bacteriostatic water or sterile saline
• After reconstitution: refrigerate at 2–8°C, protect from light, use within 30 days
• Do not freeze reconstituted solutions

Disclaimer

Selank, Semax, Epithalon, and DSIP are sold strictly for in vitro and preclinical research purposes. They are not approved drug products and are not intended for human therapeutic use. This content is for scientific and educational informational purposes only and does not constitute medical advice or a recommendation for use.

References

• Semenova TP, et al. (2010). Selank and its analog tuftsin modulate the expression of genes related to the serotoninergic system. Doklady Biological Sciences, 433(1), 231–234.
• Uchakina ON, et al. (2008). Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(5), 71–75.
• Zozulya AA, et al. (2001). The regulatory role of enkephalins and selank in the functioning of the immune system. Immunology Letters, 76(2), 85–92.
• Dolotov OV, et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60.
• Manukhina EB, et al. (2016). Neuroprotective and anxiolytic effects of the melanocortin receptor agonist Semax in experimental ischemia. Neural Plasticity, 2016, 8346901.
• Khavinson VKh, et al. (2002). Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinology Letters, 23(4), 334–338.
• Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters, 24(3–4), 233–240.
• Monnier M, Schoenenberger GA. (1977). Characterization, sequence, synthesis and specificity of the delta-sleep inducing peptide. European Journal of Biochemistry, 74(3), 561–571.
• Bjartmar L, et al. (2000). Neuroanatomical localization and functional activity of the DSIP in mammalian brain. Peptides, 21(9), 1–14.